CDISC and their funding partner, the National Organization for Rare Disorders, have announced the public review of version 1.0 of the Rare Diseases Therapeutic Area User Guide (TAUG-Rare Diseases). This guide provides valuable insights and guidance for CDASH, SDTM, and…

🔬 We successfully organized and conducted the iDMC for Phase I, Randomized, Double Blind, Placebo-Controlled, Safety, Reactogenicity, and Immunogenicity Trial of the SARS-CoV-2 Vaccine in Healthy Volunteers. This milestone marks a significant step forward in the fight against COVID-19. 📃…